Parasitic worm infections can reduce the susceptibility of immune cells to HIV infection, according to new University of Liverpool research.
A new injectable HIV drug could mean that patients no longer have to medicate themselves on a daily basis, according to a clinical trial led by researchers from Queen Mary University of London and Barts Health NHS Trust, and sponsored by Viiv healthcare.
A class of anti-inflammatory drugs already FDA-approved for rheumatoid arthritis could “purge” the reservoir of infected immune cells in people infected by HIV, according to new research.
A permanent cure for HIV infection remains elusive due to the virus’s ability to hide away in latent reservoirs. But now, in new research published in print May 3 in the journal Molecular Therapy, scientists at the Lewis Katz School of Medicine at Temple University (LKSOM) and the University of Pittsburgh show that they can excise HIV DNA from the genomes of living animals to eliminate further infection. They are the first to perform the feat in three different animal models, including a «humanized» model in which mice were transplanted with human immune cells and infected with the virus.
HIV cure research to date has focused on clearing the virus from T cells, a type of white blood cell that is an essential part of the immune system. Yet investigators in the division of infectious diseases at the University of North Carolina School of Medicine have found the virus persists in HIV-infected macrophages.